Y
Yasuhiro Funahashi
Researcher at Eisai
Publications - 119
Citations - 5007
Yasuhiro Funahashi is an academic researcher from Eisai. The author has contributed to research in topics: Lenvatinib & Angiogenesis. The author has an hindex of 28, co-authored 114 publications receiving 3891 citations. Previous affiliations of Yasuhiro Funahashi include National Archives and Records Administration.
Papers
More filters
Journal ArticleDOI
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
Junji Matsui,Yuji Yamamoto,Yasuhiro Funahashi,Akihiko Tsuruoka,Tatsuo Watanabe,Toshiaki Wakabayashi,Toshimitsu Uenaka,Makoto Asada +7 more
TL;DR: KIT signaling has a role in tumor angiogenesis of SCF‐producing H146 cells, and E7080 causes regression of H146 tumors as a result of antiangiogenic activity mediated by inhibition of both KIT and VEGF receptor signaling.
Journal ArticleDOI
Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase
Junji Matsui,Yasuhiro Funahashi,Toshimitsu Uenaka,Tatsuo Watanabe,Akihiko Tsuruoka,Makoto Asada +5 more
TL;DR: Simultaneous inhibition of both VEGF-R2 and VEGf-R3 kinases by E7080 may be a promising new strategy to control regional lymph node and distant lung metastases.
Journal ArticleDOI
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama,Junji Matsui,Kotaro Kodama,Naoko Hata-Sugi,Takayuki Kimura,Kiyoshi Okamoto,Yukinori Minoshima,Masao Iwata,Yasuhiro Funahashi +8 more
TL;DR: Data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.
Journal ArticleDOI
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.
Yuji Yamamoto,Junji Matsui,Tomohiro Matsushima,Hiroshi Obaishi,Kazuki Miyazaki,Katsuji Nakamura,Osamu Tohyama,Taro Semba,Atsumi Yamaguchi,Sachi Hoshi,Fusayo Mimura,Toru Haneda,Yoshio Fukuda,Junichi Kamata,Keiko Takahashi,Masayuki Matsukura,Toshiaki Wakabayashi,Makoto Asada,Kenichi Nomoto,Tatsuo Watanabe,Zoltan Dezso,Kentaro Yoshimatsu,Yasuhiro Funahashi,Akihiko Tsuruoka +23 more
TL;DR: Results indicated that Lenvatinib inhibited VEGF- and FGF-driven angiogenesis and showed a broad spectrum of antitumor activity with a wide therapeutic window.
Journal ArticleDOI
Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states
Taku Yoshida,Yoichi Ozawa,Takayuki Kimura,Yoshiaki Sato,Galina Kuznetsov,Shanqin Xu,Mai Uesugi,Sergei Agoulnik,Noel Taylor,Yasuhiro Funahashi,Junji Matsui +10 more
TL;DR: Eribulin exerted significant effects on EMT/MET-related pathway components in human breast cancer cells in vitro and in vivo, consistent with a phenotypic switch from mesenchymal to epithelial states, and corresponding to observed decreases in migration and invasiveness in vitro as well as experimental metastasis in vivo.